CTRI/2021/02/030935尚未招募4 期
Evaluation of effectiveness and safety of first line drugs used in the treatment ofperipheral neuropathy among elderly population - A randomized, open-label, activecomparator pilot study
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Age more than sixty years of either sex
- •1. Patients newly diagnosed as a case of peripheral neuropathy according to Modified
- •Toronto Clinical Neuropathy (score > 11) or known case of peripheral neuropathy
- •without any treatment for past 8 weeks
- •2. Patient willing to participate in the study by giving Informed consent
排除标准
- •1. Age < 60years
- •2. Declined consent.
- •3. Acute serious illness (like Myocardial Infarction, Stroke, Sepsis, Electrolyte
- •disturbances)
- •4. Known case of any malignancy
- •5. H/o alcohol consumption ( >100 gm/day) for more than three years
- •6. Patients with score of 11 in modified Toronto Clinical Neuropathy Score
- •7. Serum Aminotransferase (ALT) > 3 times of upper limit of normal level
- •8. Chronic Kidney disease or Estimated Glomerular Filtration Rate (eGFR) < 45
- •ml/min/1.73m2
- •9. Patients with documented or clinical features of Vitamin B12 deficiency
- •10. H/o raised intra-ocular pressure / acute angle closure glaucoma
- •11. H/o any major psychiatric disorders
- •12. H/o treatment with Monoamine Oxidase Inhibitors in past 14 days
- •13. History suggestive of lower urinary tract symptoms or Benign prostatic hyperplasia
研究者
相似试验
招募中
2 期
Evaluation of safety and the effectiveness of Prime (U+) Urea 5% Shampoo, in improving of dryness and itching in sensitive scalpIRCT20190210042676N19Akhavi laboratory19
招募中
1 期
A Phase I Study to Evaluate the Safety and Efficacy of Mesenchymal Stromal Cells (MSC) for Treating Chronic Obstructive Pulmonary Disease (COPD)COPDRespiratory - Chronic obstructive pulmonary diseaseACTRN12614000731695Royal Perth Hospital10
进行中（未招募）
1 期
STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH CHOP AND LENALIDOMIDE (Rev-CHOP) WITH PREVIOUSLY UNTREATED ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL).Angioimmunoblastic T-cell Lymphoma (AITL)MedDRA version: 20.0 Level: PT Classification code 10002449 Term: Angioimmunoblastic T-cell lymphoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001356-10-BEYSARC70
已完成
1 期
DCB-DM101 in Participants with Type 2 Diabetes MellitusType 2 Diabetes MellitusACTRN12618001140246VitNovo Australia Pty Ltd24
进行中（未招募）
1 期
aEUCTR2019-004883-23-FRAPHP